Efficacy of Coherence Therapy for Procrastination (CTFORPRO)

June 1, 2015 updated by: Dr. Guillem Feixas, University of Barcelona

Efficacy of Coherence Therapy for Procrastination: a Randomized Controlled Trial

The purpose of this study is to determine the efficacy of Coherence Therapy in treating procrastination. For that, this intervention is compared to Cognitive-Behavioral Therapy which was already proved to be efficacious in treating this problem. The method used is a randomized controlled trial.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Procrastination is a recognized difficulty that entails negative outcomes regarding performance and subjective well-being. In order to find effective treatments for procrastination, the present study wants to test the efficacy of Coherence Therapy, compared with Cognitive Behavioral Therapy. Procrastination, negative emotional states and cognitive structure will be assessed in pre-treatment and post-treatment evaluation. A total of 30 students will be randomly assigned to Coherence Therapy (n=15) or Cognitive Behavioral Therapy (n=15). In both forms of treatment students will receive three weekly sessions and one more session six to seven weeks after the third session. The treatment will be provided by trained psychotherapists. Findings would clarify the effectiveness of Coherence Therapy for the treatment of procrastination and the change of emotional states and cognitive structure of the students after the treatment.

Study Type

Interventional

Enrollment (Actual)

31

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Catalonia
      • Barcelona, Catalonia, Spain, 08035
        • University of Barcelona

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 22 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Being a student
  • 19-26 years old
  • A score above 51 on the General Procrastination Scale

Exclusion Criteria:

  • Being currently under a psychological treatment
  • Being diagnosed lately with any mental disorder
  • Mental retardation
  • Substantial visual, hearing or cognitive deficits
  • Psychotic symptoms
  • Organic brain dysfunction

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Coherence Therapy
Individual treatment with Coherence Therapy: three one-hour sessions + one booster session.
Behavioral: Coherence Therapy
Manualized individual treatment (3 + 1 one-hour sessions)
Active Comparator: Cognitive Behavioral Therapy
Individual treatment with Cognitive Behavioral Therapy: three one-hour sessions + one booster session.
Behavioral: Cognitive Behavioral Therapy
Manualized individual treatment (3 + 1 one-hour sessions)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
General Procrastination Scale (Lay, 1986)
Time Frame: Post-treatment assessment (10-12 weeks)
Change from Baseline in General Procrastination Scale measured before and after the therapy in order to determine the level of general procrastination.
Post-treatment assessment (10-12 weeks)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Repertory Grid Technique (Kelly, 1995; adaptation of Feixas & Cornejo, 1996)
Time Frame: Post-treatment assessment (10-12 weeks)
Change in cognitive structure measured by Kelly's Repertory Grid Technique.
Post-treatment assessment (10-12 weeks)
Depression, Anxiety and Stress Scale (Lovibond & Lovibond, 1995)
Time Frame: Post-treatment assessment (10-12 weeks)
Change from Baseline in negative emotional states on three dimensions: depression, anxiety and stress.
Post-treatment assessment (10-12 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Barcelona

Investigators

  • Principal Investigator: Guillem Feixas, Ph.D., University of Barcelona

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2014

Primary Completion (Actual)

June 1, 2014

Study Completion (Actual)

June 1, 2014

Study Registration Dates

First Submitted

February 6, 2014

First Submitted That Met QC Criteria

February 6, 2014

First Posted (Estimate)

February 10, 2014

Study Record Updates

Last Update Posted (Estimate)

June 2, 2015

Last Update Submitted That Met QC Criteria

June 1, 2015

Last Verified

June 1, 2015

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • CTprocrast

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Procrastination

Clinical Trials on Coherence Therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe